Bio-Thera Claims A World First With Chinese Tocilizumab Approval

Actemra/RoActemra Gets NMPA Nod; Offers Option For COVID-19 Treatment

 
• By Dave Wallace

Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.

First Place Gold Medal
Bio-Thera can boast a world first with its tocilizumab approval • Source: Shutterstock

More from Biosimilars

More from Products